O	0	6	Effect
O	7	9	of
O	10	14	once
O	14	15	-
O	15	21	weekly
B-intervention	22	29	epoetin
I-intervention	30	34	beta
O	35	37	on
O	38	46	survival
O	47	49	in
B-eligibility	50	58	patients
I-eligibility	59	63	with
I-eligibility	64	74	metastatic
I-eligibility	75	81	breast
I-eligibility	82	88	cancer
I-eligibility	89	98	receiving
I-eligibility	99	112	anthracycline
I-eligibility	112	113	-
I-eligibility	114	117	and
I-eligibility	117	118	/
I-eligibility	118	120	or
I-eligibility	121	127	taxane
I-eligibility	127	128	-
I-eligibility	128	133	based
I-eligibility	134	146	chemotherapy
O	146	147	:
O	148	155	results
O	156	158	of
O	159	162	the
O	163	169	Breast
O	170	176	Cancer
O	176	177	-
O	177	183	Anemia
O	184	187	and
O	188	191	the
O	192	197	Value
O	198	200	of
O	201	215	Erythropoietin
O	216	217	(
O	217	222	BRAVE
O	222	223	)
O	224	229	study
O	229	230	.

O	231	234	The
O	235	241	Breast
O	242	248	Cancer
O	248	249	-
O	249	255	Anemia
O	256	259	and
O	260	263	the
O	264	269	Value
O	270	272	of
O	273	287	Erythropoietin
O	288	289	(
O	289	294	BRAVE
O	294	295	)
O	296	301	study
O	302	311	evaluated
O	312	319	whether
O	320	327	epoetin
O	328	332	beta
O	333	338	would
O	339	346	improve
O	347	355	survival
O	356	358	in
O	359	367	patients
O	368	372	with
O	373	383	metastatic
O	384	390	breast
O	391	397	cancer
O	398	399	(
O	399	402	MBC
O	402	403	)
O	403	404	.

O	405	410	BRAVE
O	411	414	was
O	415	417	an
O	418	422	open
O	422	423	-
O	423	428	label
O	428	429	,
O	430	440	randomized
O	440	441	,
O	442	453	multicenter
O	454	459	study
O	460	462	in
O	463	471	patients
O	472	476	with
O	477	480	MBC
O	481	488	treated
O	489	493	with
O	494	507	anthracycline
O	507	508	-
O	509	512	and
O	512	513	/
O	513	515	or
O	516	522	taxane
O	522	523	-
O	523	528	based
O	529	541	chemotherapy
O	541	542	.

O	543	551	Patients
O	552	553	(
O	553	563	hemoglobin
O	564	565	[
O	565	567	Hb
O	567	568	]
O	569	570	<
O	571	573	12
O	573	574	.
O	574	575	9
O	576	577	g
O	577	578	/
O	578	580	dL
O	580	581	)
O	582	586	were
O	587	595	randomly
O	596	604	assigned
O	605	606	(
O	606	607	1
O	607	608	:
O	608	609	1
O	609	610	)
O	611	613	to
O	614	621	epoetin
O	622	626	beta
O	627	629	30
O	629	630	,
O	630	633	000
O	634	635	U
O	636	650	subcutaneously
O	651	655	once
O	656	662	weekly
O	663	665	or
B-control	666	673	control
O	674	677	for
O	678	680	24
O	681	686	weeks
O	686	687	.

O	688	691	The
O	692	699	primary
O	700	708	efficacy
O	709	717	variable
O	718	721	was
B-outcome-Measure	722	729	overall
I-outcome-Measure	730	738	survival
O	738	739	.

O	740	749	Secondary
O	750	758	efficacy
O	759	767	outcomes
O	768	776	included
B-outcome-Measure	777	788	progression
I-outcome-Measure	788	789	-
I-outcome-Measure	789	793	free
I-outcome-Measure	794	802	survival
O	802	803	,
B-outcome-Measure	804	815	transfusion
I-outcome-Measure	815	816	-
I-outcome-Measure	817	820	and
I-outcome-Measure	821	827	severe
I-outcome-Measure	828	834	anemia
I-outcome-Measure	834	835	-
I-outcome-Measure	835	839	free
I-outcome-Measure	840	848	survival
O	848	849	,
B-outcome-Measure	850	852	Hb
I-outcome-Measure	853	861	response
O	861	862	,
B-outcome-Measure	863	869	safety
O	869	870	,
O	871	874	and
B-outcome-Measure	875	882	quality
I-outcome-Measure	883	885	of
I-outcome-Measure	886	890	life
I-outcome-Measure	891	892	(
I-outcome-Measure	892	895	QoL
I-outcome-Measure	895	896	)
O	896	897	.

O	898	903	After
O	904	906	18
O	907	913	months
O	914	916	of
O	917	923	follow
O	923	924	-
O	924	926	up
O	926	927	,
B-iv-bin-abs	928	930	62
O	931	932	(
B-iv-bin-percent	932	934	27
I-iv-bin-percent	934	935	%
O	935	936	)
O	937	939	of
B-intervention-participants	940	943	231
O	944	952	patients
B-outcome	953	961	survived
O	962	966	with
O	967	974	epoetin
O	975	979	beta
O	980	987	therapy
O	988	991	and
B-cv-bin-abs	992	994	63
O	995	996	(
B-cv-bin-percent	996	998	27
I-cv-bin-percent	998	999	%
O	999	1000	)
O	1001	1003	of
B-control-participants	1004	1007	232
O	1008	1012	with
O	1013	1020	control
O	1020	1021	.

O	1022	1024	No
O	1025	1035	difference
O	1036	1039	was
O	1040	1048	detected
O	1049	1051	in
B-outcome	1052	1059	overall
I-outcome	1060	1068	survival
O	1069	1070	(
O	1070	1076	hazard
O	1077	1082	ratio
O	1083	1084	[
O	1084	1086	HR
O	1086	1087	]
O	1088	1089	=
O	1090	1091	1
O	1091	1092	.
O	1092	1094	07
O	1094	1095	;
O	1096	1098	95
O	1098	1099	%
O	1100	1102	CI
O	1102	1103	,
O	1104	1105	0
O	1105	1106	.
O	1106	1108	87
O	1109	1111	to
O	1112	1113	1
O	1113	1114	.
O	1114	1116	33
O	1116	1117	,
O	1118	1119	P
O	1120	1121	=
O	1122	1123	.
O	1123	1126	522
O	1126	1127	)
O	1128	1130	or
B-outcome	1131	1142	progression
I-outcome	1142	1143	-
I-outcome	1143	1147	free
I-outcome	1148	1156	survival
O	1157	1158	(
O	1158	1160	HR
O	1161	1162	=
O	1163	1164	1
O	1164	1165	.
O	1165	1167	07
O	1167	1168	;
O	1169	1171	95
O	1171	1172	%
O	1173	1175	CI
O	1175	1176	,
O	1177	1178	0
O	1178	1179	.
O	1179	1181	89
O	1182	1184	to
O	1185	1186	1
O	1186	1187	.
O	1187	1189	30
O	1189	1190	,
O	1191	1192	P
O	1193	1194	=
O	1195	1196	.
O	1196	1199	448
O	1199	1200	)
O	1200	1201	.

O	1202	1207	There
O	1208	1211	was
O	1212	1213	a
O	1214	1227	statistically
O	1228	1239	significant
O	1240	1247	benefit
O	1248	1250	on
B-outcome	1251	1262	transfusion
I-outcome	1262	1263	-
I-outcome	1264	1267	and
I-outcome	1268	1274	severe
I-outcome	1275	1281	anemia
I-outcome	1281	1282	-
I-outcome	1282	1286	free
I-outcome	1287	1295	survival
O	1296	1304	compared
O	1305	1309	with
O	1310	1317	control
O	1318	1319	(
O	1319	1321	HR
O	1322	1323	=
O	1324	1325	0
O	1325	1326	.
O	1326	1328	59
O	1328	1329	;
O	1330	1331	P
O	1332	1333	=
O	1334	1335	.
O	1335	1339	0097
O	1339	1340	)
O	1340	1341	.

B-outcome	1342	1348	Median
I-outcome	1349	1351	Hb
I-outcome	1352	1357	level
O	1358	1367	increased
O	1368	1372	with
O	1373	1380	epoetin
O	1381	1385	beta
O	1386	1387	(
B-iv-cont-median	1387	1389	11
I-iv-cont-median	1389	1390	.
I-iv-cont-median	1390	1391	7
I-iv-cont-median	1392	1393	g
I-iv-cont-median	1393	1394	/
I-iv-cont-median	1394	1396	dL
B-outcome	1397	1399	at
I-outcome	1400	1408	baseline
O	1409	1411	to
B-iv-cont-median	1412	1414	13
I-iv-cont-median	1414	1415	.
I-iv-cont-median	1415	1416	3
I-iv-cont-median	1417	1418	g
I-iv-cont-median	1418	1419	/
I-iv-cont-median	1419	1421	dL
B-outcome	1422	1424	at
I-outcome	1425	1427	24
I-outcome	1428	1433	weeks
O	1433	1434	)
O	1435	1438	but
O	1439	1442	did
O	1443	1446	not
O	1447	1453	change
O	1454	1458	with
O	1459	1466	control
O	1467	1468	(
B-cv-cont-median	1468	1470	11
I-cv-cont-median	1470	1471	.
I-cv-cont-median	1471	1472	5
O	1473	1474	v
B-cv-cont-median	1475	1477	11
I-cv-cont-median	1477	1478	.
I-cv-cont-median	1478	1479	4
I-cv-cont-median	1480	1481	g
I-cv-cont-median	1481	1482	/
I-cv-cont-median	1482	1484	dL
O	1484	1485	)
O	1485	1486	.

O	1487	1495	Patients
O	1496	1505	receiving
O	1506	1513	epoetin
O	1514	1518	beta
O	1519	1530	experienced
O	1531	1535	more
B-outcome	1536	1550	thromboembolic
I-outcome	1551	1557	events
I-outcome	1558	1559	(
I-outcome	1559	1563	TEEs
I-outcome	1563	1564	)
O	1565	1573	compared
O	1574	1578	with
O	1579	1587	controls
O	1588	1589	(
B-iv-bin-percent	1589	1591	13
I-iv-bin-percent	1591	1592	%
O	1593	1594	v
B-cv-bin-abs	1595	1596	6
I-cv-bin-abs	1596	1597	%
O	1597	1598	;
O	1599	1600	P
O	1601	1602	=
O	1603	1604	.
O	1604	1607	012
O	1607	1608	)
O	1609	1613	with
O	1614	1616	no
O	1617	1627	difference
O	1628	1630	in
B-outcome	1631	1638	serious
I-outcome	1639	1643	TEEs
O	1644	1645	(
B-iv-bin-percent	1645	1646	4
I-iv-bin-percent	1646	1647	%
O	1648	1649	v
B-cv-bin-percent	1650	1651	3
I-cv-bin-percent	1651	1652	%
O	1652	1653	)
O	1653	1654	.

O	1655	1662	Epoetin
O	1663	1667	beta
O	1668	1671	did
O	1672	1675	not
O	1676	1689	significantly
O	1690	1697	improve
B-outcome	1698	1701	QoL
O	1702	1704	in
O	1705	1709	this
O	1710	1715	study
O	1716	1721	where
O	1722	1730	patients
O	1731	1734	had
O	1735	1736	a
O	1737	1741	high
O	1742	1750	baseline
O	1751	1753	Hb
O	1754	1759	value
O	1759	1760	.

O	1761	1763	In
O	1764	1772	patients
O	1773	1777	with
O	1778	1781	MBC
O	1782	1791	receiving
O	1792	1804	chemotherapy
O	1805	1808	and
O	1809	1816	initial
O	1817	1819	Hb
O	1820	1824	less
O	1825	1829	than
O	1830	1832	12
O	1832	1833	.
O	1833	1834	9
O	1835	1836	g
O	1836	1837	/
O	1837	1839	dL
O	1839	1840	,
O	1841	1848	epoetin
O	1849	1853	beta
O	1854	1863	increased
O	1864	1866	Hb
O	1866	1867	.

O	1868	1870	No
O	1871	1881	difference
O	1882	1885	was
O	1886	1894	detected
O	1895	1897	in
B-outcome	1898	1905	overall
I-outcome	1906	1914	survival
O	1914	1915	.

O	1916	1923	Because
O	1924	1926	of
O	1927	1930	its
O	1931	1942	superiority
O	1943	1949	design
O	1949	1950	,
O	1951	1955	this
O	1956	1961	study
O	1962	1968	cannot
O	1968	1969	,
O	1970	1977	however
O	1977	1978	,
O	1979	1986	exclude
O	1987	1997	clinically
O	1998	2007	important
O	2008	2019	differences
O	2020	2022	in
O	2023	2031	survival
O	2032	2036	with
O	2037	2045	absolute
O	2046	2055	certainty
O	2055	2056	.
